| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5587126 | Diabetes Research and Clinical Practice | 2017 | 29 Pages |
Abstract
The ICER for SAPÂ +Â LGS versus CSII falls below commonly cited willingness-to-pay thresholds. Therefore, in Denmark, the use of SAPÂ +Â LGS is likely to be considered cost-effective relative to CSII for patients with T1D who are either hyperglycemic, despite CSII use, or who experience frequent severe hypoglycemic events.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
S. Roze, S. de Portu, J. Smith-Palmer, A. Delbaere, W. Valentine, M. Ridderstråle,